Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,704.00
(
-0.39%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
113.88
(
6.85%
)
Bitcoin
70,197.37
(
-1.47%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 36
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: DewDiligence post# 73230

Sunday, 02/15/2009 9:56:54 PM

Sunday, February 15, 2009 9:56:54 PM

Post# of 257257
Dew,

Perhaps this is a simple-minded question (not unusual coming from me): But why, if IDX 899 is shown to be clinically superior to Sustiva, wouldn't Gilead want to strike up a deal with GSK and replace Sustiva (and BMY) in the Atripla combination?

Bladerunner
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now